Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is February 19, 2026, covering a share purchase executed on February 18, 2026. The transaction was conducted through BNP Paribas SA as part of GSK's existing share buyback programme under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for this transaction include:
- Shares Purchased: 410,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,244.00 GBp; highest price paid was 2,281.00 GBp.
- Average Price: Volume-weighted average price paid was 2,268.77 GBp.
- Treasury Holdings: Following this purchase, GSK holds 240,721,094 ordinary shares in treasury.
- Shares in Issue: 4,075,421,475 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.91% of total voting rights.
Revenue, profit, cash flow, margins, debt, and liquidity figures are not provided in this specific filing.
Material Changes
Since February 17, 2026, GSK has purchased a total of 830,000 ordinary shares. The purchase reported herein increased the company's treasury share count and reduced the number of shares in issue. The filing confirms the percentage of voting rights attributable to treasury shares is now 5.91%.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q4 Results for 2025.
Important Facts for Investors
- Verify the total remaining authorization under the existing buyback programme, as this filing only details a specific tranche of purchases.
- Note that treasury shares (240.7 million) do not carry voting rights, impacting the denominator for shareholder notification thresholds under FCA rules.
- Confirm the total cost of the buyback programme by aggregating this transaction with prior purchases, as this filing does not state the total programme value.
- Review the referenced 2024 Form 20-F and 2025 Q4 results for comprehensive financial performance and risk factors not included in this transaction report.